MORRISVILLE, NC, June 09, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the presentation of experimental use data for the powder for Inhalation YUTREPIA™ (treprostinil), formerly known as LIQ861, at the Pulmonary Hypertension Association (PHA) International Conference and Scientific Session in Atlanta, Georgia, June 9-11, 2022.
Poster no. 1036: Quality of life (QoL) in patients with PAH receiving inhaled dry powder treprostinil (LIQ861) in the INSPIRE study. Presented during the poster session by Martha Kingman, FNP-C, DNP, of the University of Texas Southwestern Medical Center in Dallas, TX.
Dr. Kingman will also present the data in oral form during Lightening-Round presentations on Thursday, June 9, from 5:50 p.m. to 6:00 p.m.
Scott Moomaw, Senior Vice President of Liquidia, said, “It has been well documented that patients with PAH have a severely impaired health-related quality of life. Data presented today help demonstrate that YUTREPIA™ can provide a clinically meaningful improvement in quality of life, whether starting prostacyclin therapy for the first time or switching from another inhaled form . We are sincerely grateful to patients and the medical community for their support in our clinical trials as we seek to address unmet needs in the treatment of PAH.
The presentation poster is available on the Company’s website at https://liquidia.com/products-and-pipeline/publications.
About YUTREPIA™ (Treprostinil) Inhalation Powder
YUTREPIA is an experimental inhaled dry powder formulation of treprostinil delivered by a proven, convenient, palm-sized device. On November 5, 2021, the FDA issued interim approval for YUTREPIA, which is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity in adult patients with functional class II symptoms -III from the New York Heart Association (NYHA). YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, and which are designed for optimal deposition in the lungs after oral inhalation. Liquidia has completed INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multicenter Phase 3 clinical study of YUTREPIA in patients diagnosed with PAH who have never received inhaled treprostinil or are on transition from Tyvaso (nebulized treprostinil). YUTREPIA was previously called LIQ861 in experimental studies.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® technology. The Company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH markets pharmaceutical products to treat lung diseases, such as generic injectable treprostinil. For more information, visit www.liquidia.com.
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Liquidia cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to, the impact of the coronavirus (COVID-19) pandemic on our company, financial condition and our operating results; and other risks and uncertainties identified in the Company’s filings with the United States Securities and Exchange Commission. Forward-looking statements reflect our analysis only as of the date indicated, and Liquidia undertakes no obligation to update or revise these statements, except as required by law.
Contact details for media and investors
Senior Vice President, Corporate Development and Strategy
Copyright 2022 GlobeNewswire, Inc.